 Connection
Margaret Macy to Topotecan
This is a "connection" page, showing publications Margaret Macy has written about Topotecan.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.176 |
|
|
|
-
Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
Score: 0.060
-
Morgenstern DA, Barone G, Corradini N, Federico SM, Flotho C, Gerber NU, Khaw SL, Macy ME, Place AE, Vo KT, Badawi M, Chen X, Luo A, Rocco MA, Ross JA, Scherer F, Sunkersett G, Onishi M, Goldsmith KC. Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study. Pediatr Blood Cancer. 2026 May; 73(5):e70178.
Score: 0.060
-
DuBois SG, Ogawa C, Moreno L, Mossé YP, Fischer M, Ryan AL, Vo KT, De Wilde B, Rubio-San-Simon A, Macy ME, Howell L, Shusterman S, Corradini N, Luksch R, Aerts I, Foster JH, Weiss BD, Karthik CP, Yuen E, Avsar E, Park JR, Marachelian A. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
Score: 0.056
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|